MedPath

Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart surgery

Phase 2
Recruiting
Conditions
Atrial fibrillation after heart surgery.
Paroxysmal atrial fibrillation
Registration Number
IRCT20120520009801N9
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
160
Inclusion Criteria

Candidates for heart surgery including CABG or valve replacement
70 yr > age > 18 yr
Taking ACEIs/ARBs, beta-blockers, statins and aspirin for CABG patients

Exclusion Criteria

History of taking empagliflozin drug before surgery
Severe heart failure (NYHA Class IV)
Renal failure (30 = GFR)
Hepatic failure (hepatic enzymes > 3 times of upper normal limit )
pregnancy
Have pacemaker
Have AF rhythm
History of heart surgery
Very thin people (BMI = 18.5 kg/m2)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of atrial fibrillation. Timepoint: Through 72 hrs after heart surgery. Method of measurement: Holter monitoring.
Secondary Outcome Measures
NameTimeMethod
C-Reactive Protein (CRP) blood concentration. Timepoint: Before surgery and 3 days after surgery. Method of measurement: Laboratory.;The incidence of ventricular and supra-ventricular arrhythmias. Timepoint: Through 72 hrs after heart surgery. Method of measurement: Holter monitoring.;Lenght of hospital stay. Timepoint: From heart surgery to discharge. Method of measurement: Counting of hospitalizations days.
© Copyright 2025. All Rights Reserved by MedPath